Inventor
KNACKMUSS STEFAN
DE15 patents
⚠️ This page may combine multiple inventors who share the name “KNACKMUSS STEFAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AFFIMED GMBH
6 patentsUS9701750B2Jul 11, 2017
Anti-CD16 binding molecules
AFFIMED GMBH11 citations82
US10066015B2Sep 4, 2018
CD3 binding domains
AFFIMED GMBH10 citations79
US10273309B2Apr 30, 2019
Antibody binding sites specific for EGFRvIII
AFFIMED GMBH2 citations71
US12264198B2Apr 1, 2025
Tandem diabody for CD16A-directed NK-cell engagement
AFFIMED GMBH0 citations60
US11180558B2Nov 23, 2021
Tandem diabody for CD16A-directed NK-cell engagement
AFFIMED GMBH0 citations60
US11167029B2Nov 9, 2021
Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
AFFIMED GMBH0 citations56
AMPHIVENA THERAPEUTICS INC
3 patentsUS9212225B1Dec 15, 2015
Bispecific CD33 and CD3 binding proteins
AMPHIVENA THERAPEUTICS INC17 citations89
US9803029B2Oct 31, 2017
Bispecific CD33 and CD3 binding proteins
AMPHIVENA THERAPEUTICS INC11 citations81
US10626190B2Apr 21, 2020
Bispecific CD33 and CD3 binding proteins
AMPHIVENA THERAPEUTICS INC3 citations70
AFFIMED THERAPEUTICS AG
3 patentsUS7812136B2Oct 12, 2010
Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa
AFFIMED THERAPEUTICS AG18 citations88
US7507797B2Mar 24, 2009
Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
AFFIMED THERAPEUTICS AG11 citations78
US7901677B1Mar 8, 2011
Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types
AFFIMED THERAPEUTICS AG1 citations47